Cargando…
SARS-CoV-2 Vaccination Effectiveness in Rituximab-Treated Patients Affected by Pemphigus Vulgaris
Autores principales: | Fenizia, Claudio, Moltrasio, Chiara, Ottobrini, Luisa, Utyro, Olga, Genovese, Giovanni, Vanetti, Claudia, Trabattoni, Daria, Marzano, Angelo V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883068/ https://www.ncbi.nlm.nih.gov/pubmed/36716924 http://dx.doi.org/10.1016/j.jid.2022.12.023 |
Ejemplares similares
-
Rituximab in the Treatment of Pemphigus Vulgaris
por: Zakka, Labib R., et al.
Publicado: (2012) -
Refractory pemphigus vulgaris treated with rituximab and mycophenolate
mofetil
por: Biot, Stephanie Del Rio Navarrete, et al.
Publicado: (2014) -
Rituximab therapy improves recalcitrant Pemphigus vulgaris
por: Noormohammadpour, Pedram, et al.
Publicado: (2015) -
Cerebral toxoplasmosis after rituximab for pemphigus vulgaris
por: Lee, Erica B., et al.
Publicado: (2019) -
AZD-1222/rituximab: Pemphigus vulgaris and pemphigus vulgaris flare-up: 2 case reports
Publicado: (2022)